What lies behind chemotherapy-induced ovarian toxicity?

Reproduction

Volumn 144, Issue 2, 2012, Pages 153-163

  Ben Aharon, Irit ^a,b   Shalgi, Ruth ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GLUTATHIONE; GOSERELIN; IMATINIB; METHOTREXATE; PACLITAXEL; PHOSPHORAMIDE MUSTARD; PROCARBAZINE; TAMOXIFEN; TRASTUZUMAB; VINCRISTINE;

ADJUVANT THERAPY; AMENORRHEA; ANEUPLOIDY; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVOR; CHOROID MELANOMA; COLORECTAL CANCER; CONGENITAL MALFORMATION; CORRELATION ANALYSIS; CRANIOFACIAL MALFORMATION; DRUG MEGADOSE; DRUG SENSITIVITY; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; FEMALE SUBFERTILITY; FIBROSIS; GERM CELL; GRANULOSA CELL; HODGKIN DISEASE; HUMAN; HYPOGONADISM; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INDUCTION CHEMOTHERAPY; INFERTILITY THERAPY; LEUKEMIA; LUNG HYPOPLASIA; METASTASIS; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOHYDRAMNIOS; OVARIAN RESERVE; OVARIAN TOXICITY; OVARY DISEASE; OVARY FOLLICLE; OXIDATIVE STRESS; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKELETON MALFORMATION; SKULL IRRADIATION; TOXICITY; WHOLE BODY RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG THERAPY; FEMALE; FERTILITY; HUMANS; MODELS, BIOLOGICAL; OVARIAN DISEASES;

EID: 84864365750     PISSN: 14701626     EISSN: 17417899     Source Type: Journal    
DOI: 10.1530/REP-12-0121     Document Type: Review

References (94)

1. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC & Partridge AH 2010 The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116 791-798. (doi:10.1002/cncr.24835)
2. Anderson RA & Cameron DA 2007 Assessment of the effect of chemotherapy on ovarian function in women with breast cancer. Journal of Clinical Oncology 25 1630-1631 (author reply 1632). (doi:10.1200/JCO.2006.09. 3666)
3. Anderson RA & Cameron DA 2011 Pretreatment serum anti-Müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. Journal of Clinical Endocrinology and Metabolism 96 1336-1343. (doi:10.1210/jc.2010-2582)
4. Ataya K, Rao LV, Lawrence E & Kimmel R 1995 Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion on rhesus monkeys. Biology of Reproduction 52 365-372. (doi:10.1095/biolreprod52.2.365)
5. Azem F, Amit A, Merimsky O & Lessing JB 2004 Successful transfer of frozen-thawed embryos obtained after subtotal colectomy for colorectal cancer and before fluorouracil-based chemotherapy. Gynecologic Oncology 93 263-265. (doi:10.1016/j.ygyno.2003.12.030)
6. Bar-Joseph H, Ben-Aharon I, Rizel S, Stemmer SM, Tzabari M & Shalgi R 2010 Doxorubicin-induced apoptosis in germinal vesicle oocytes. Reproductive Toxicology 30 566-572. (doi:10.1016/j.reprotox.2010.07.003)
7. Bar-Joseph H, Ben-Aharon I, Tsarfaty G, Tzabari M, Stemmer SM & Shalgi R 2011 Novel in vivo imaging of acute chemotherapy-induced vascular toxicity. PLoS One 6 e23492.
8. Ben-Aharon I, Bar-Joseph H, Tzarfaty G, Kuchinsky L, Rizel S, Stemmer SM & Shalgi R 2010 Doxorubicin-induced ovarian toxicity. Reproductive Biology and Endocrinology 4 8-20.
9. Berliere M, Dalenc F,Malingret N, Piette P, Roche H, Donnez J, Symann M, Kerger J & Machiels JP 2008 Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 8 56-64. (doi:10.1186/1471-2407-8-56)
10. Bines J, Oleske DM & Cobleigh MA 1996 Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology 14 1718-1729.
11. Blommaert FA & Saris C 1995 Detection of platinum-DNA adducts by 32P postlabelling. Nucleic Acids Research 23 1300-1306. (doi:10.1093/nar/23.8.1300)
12. Brougham MF, Crofton PM, Johnson EJ, Evans N, Anderson RA & Wallace WH 2012 Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. Journal of Clinical Endocrinology and Metabolism 97 2059-2067. (doi:10.1210/jc.2011-3180)
13. Brusamolino E, Lunghi F, Orlandi E, Astori C, Passamonti F, Baraté C, Pagnucco G, Baio A, Franchini P, Lazzarino M et al. 2000 Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. Haematologia 85 1032-1039.
14. Burstein HJ & Winer EP 2000 Primary care for survivors of breast cancer. New England Journal of Medicine 343 1086-1894. (doi:10.1056/ NEJM200010123431506)
15. Chang TK, Weber GF, Crespi CL & Waxman DJ 1993 Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Research 53 5629-5637.
16. Christopoulos C, Dimakopoulou V & Rotas E 2008 Primary ovarian insufficiency associated with imatinib therapy. New England Journal of Medicine 358 1079-1080. (doi:10.1056/NEJMc0707841)
17. Cobleigh MA, Bines J, Harris D, La Follette S, Lincoln ST &Wolter JM 1995 Amenorrhea following adjuvant chemotherapy for breast cancer. Proceedings of the American Society of Clinical Oncology 14 158 (abstract).
18. Conchon M, Sanabani SS, Serpa M, Novaes MM, Nardinelli L, Ferreira PB, Dorliac-Llacer PE & Bendit I 2010 Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Advances in Hematology. (doi:10.1155/2010/136252)
19. Critchley HO & Wallace WH 2005 Impact of cancer treatment on uterine function. Journal of the National Cancer Institute. Monographs 34 64-68. (doi:10.1093/jncimonographs/lgi022)
20. Davis AL, LitusM&MintzerDM 2005 Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Clinical Breast Cancer 6 421-424. (doi:10.3816/CBC.2005.n.046)
21. Devine PJ, Perreault SD & Luderer U 2012 Roles of reactive oxygen species and antioxidants in ovarian toxicity. Biology of Reproduction 86 27. (doi:10.1095/biolreprod.111.095224)
22. Dirven HA, van Ommen B & van Bladeren PJ 1994 Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Research 54 6215-6220.
23. Dnistrian AM, Schwartz MK, Fracchia AA, Kaufman FJ, Hakes TB & Currie VE 1983 Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer 51 803-807. (doi:10.1002/1097- 0142(19830301)51:5〈803::AID-CNCR 2820510509〉3.0.CO;2-V)
24. Domingo J, Guillén V, Ayllón Y, Martínez M, Muñoz E, Pellicer A & Garcia-Velasco JA 2012 Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertility and Sterility 97 930-934. (doi:10.1016/j. fertnstert.2012.01.093)
25. Dowsett M & Richner J 1991 Effects of cytotoxic chemotherapy on ovarian and adrenal steroidogenesis in pre-menopausal breast cancer patients. Oncology 48 215-220. (doi:10.1159/000226930)
26. Elis A, Tevet A, Yerushalmi R, Blickstein D, BairyO, Dann EJ, Blumenfeld Z, Abraham A, Manor Y, Shpilberg O et al. 2006 Fertility status among women treated for aggressive non-Hodgkin's lymphoma. Leukemia & Lymphoma 47 623-627. (doi:10.1080/10428190500353877)
27. Fornier MN, Modi S, Panageas KS, Norton L & Hudis C 2005 Incidence of chemotherapy- induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104 1575-1579. (doi:10.1002/cncr.21385)
28. Fu XW, Shi WQ, Zhang QJ, Zhao XM, Yan CL, Hou YP, Zhou GB, Fan ZQ, Suo L, Wusiman A et al. 2009 Positive effects of taxol pretreatment on morphology, distribution and ultrastructure of mitochondria and lipid droplets in vitrification of in vitro matured porcine oocytes. Animal Reproduction Science 115 158-168. (doi:10.1016/j.anireprosci.2008.12.002)
29. Gonfloni S, DiTella L, Caldarola S, Cannata SM, Klinger FG, DiBartolomeo C, Mattei M, Candi E, De Felici M, Melino G et al. 2009 Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nature Medicine 15 1179-1185. (doi:10.1038/nm.2033)
30. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M & Hood N 1999 Risk of menopause during the first year after breast cancer diagnosis. Journal of Clinical Oncology 17 2365-2370.
31. Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC, Donaldson SS, Byrne J & Robison LL 2010 Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Journal of Clinical Oncology 28 332-339. (doi:10.1200/JCO.2009.24.9037)
32. Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, Lee H, Lee ES, Kang HS & Kim SW 2009 Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Research and Treatment 115 335-342. (doi:10.1007/s10549-008-0071- 9)
33. Hart R 2008 Preservation of fertility in adults and children diagnosed with cancer. BMJ 337 a2045. (doi:10.1136/bmj.a2045)
34. Higdon RE, Marchetti F, Mailhes JB & Phillips GL 1992 The effects of cisplatin on murine metaphase II oocytes. Gynecologic Oncology 147 348-352. (doi:10.1016/0090-8258(92)90138-9)
35. Hensley ML & Ford JM 2003 Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Seminars in Hematology 40 (Suppl 2) 21-25. (doi:10.1053/shem.2003.50038)
36. Hrushesky WJ, Vyzula R & Wood PA 1999 Fertility maintenance and 5-fluorouracil timing within the mammalian fertility cycle. Reproductive Toxicology 13 413-420. (doi:10.1016/S0890-6238(99)00037-4)
37. Hutt KJ, McLaughlin EA & Holland MK 2006 Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis. Molecular Human Reproduction 12 61-69. (doi:10.1093/molehr/gal010)
38. Jang YM, Kendaiah S, Drew B, Phillips T, Selman C, Julian D & Leeuwenburgh C 2004 Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Letters 577 483-490. (doi:10.1016/j.febslet.2004.10.053)
39. Jarrell J, Young Lai EV, Barr R, McMahon A, Belbeck L & O'Connell G 1987 Ovarian toxicity of cyclophosphamide alone and in combination with ovarian irradiation in the rat. Cancer Research 47 2340-2343.
40. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T & Thun MJ 2008 Cancer statistics, 2008. CA: A Cancer Journal for Clinicians 58 71-96. (doi:10.3322/CA.2007.0010)
41. Johnson J, Canning J, Kaneko T, Pru JK & Tilly JL 2004 Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 28 145-150. (doi:10.1038/nature02316)
42. van der Kaaij MA, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser EC, Allgeier A, Meulemans B, Simons AH, Lugtenburg PJ et al. 2012 Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. Journal of Clinical Oncology 30 291-299. (doi:10.1200/JCO.2011.37.1989)
43. Kai S, Kohmura H, Hiraiwa E, Koizumi S, Ishikawa K, Kawano S, Kuroyanagi K, Hattori N, Chikazawa H & Kondoh H 1994 Reproductive and developmental toxicity studies of paclitaxel. (I) Intravenous administration to rats prior to and in the early stages of pregnancy. Journal of Toxicological Sciences 19 57-67. (doi:10.2131/jts.19.SupplementI-57)
44. Kelsey TW & Wallace WH 2010 Human ovarian reserve from conception to menopause. PLoS ONE 5 e8772. (doi:10.1371/journal.pone.0008772)
45. Kim SS, Lee JR, Jee BC, Suh CS, Kim SH, Ting A & Petroff B 2010 Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clinical Obstetrics and Gynecology 53 740-752. (doi:10.1097/GRF.0b013e3181f96cb1)
46. Kishore BK, Krane CM, Di Iulio D, Menon AG & CaciniW2000 Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria. Kidney International 58 701-711. (doi:10.1046/j.1523-1755.2000.00216.x)
47. Littley MD, Shalet SM & Beardwell CG 1989 Hypopituitarism following external radiotherapy for pituitary tumours in adults. Quarterly Journal of Medicine 70 145-160.
48. Lobo RA 2005 Potential options for preservation of fertility in women. New England Journal of Medicine 353 64-73. (doi:10.1056/NEJMra043475)
49. Madanat LM, Malila N, Dyba T, Hakulinen T, Sankila R, Boice JD Jr & Lähteenmäki PM 2008 Probability of parenthood after early onset cancer: a population-based study. International Journal of Cancer 123 2891-2898. (doi:10.1002/ijc.23842)
50. Magelssen H, Melve KK, Skjaerven R & Fossa° SD 2008 Parenthood probability and pregnancy outcome in patients with a cancer diagnosis during adolescence and young adulthood. Human Reproduction 23 178-186. (doi:10.1093/humrep/dem362)
51. Malozowski S, Nelson L & Calis KA 2008 More on ovarian insufficiency with imatinib. New England Journal of Medicine 358 2648-2649. (doi:10.1056/NEJMc080707)
52. Maneschi F, Benedetti-Panici P, Scambia G, Salerno MG, D'Agostino G & Mancuso S 1994Menstrual and hormone patterns in women treated with high-dose cisplatin and bleomycin. Gynecologic Oncology 54 345-348. (doi:10.1006/gyno. 1994.1221)
53. Marcello MF, Nuciforo G, Romeo R, Dino GD, Russo I, Russo A, Palumbo G & Schilirò G 1999 Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment. Cancer 66 2099-2104. (doi:10.1002/1097-0142(19901115)66:10〈2099::AID-CNCR2820661010O3.0. C〉;2-3)
54. Meirow D 1999 Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radiochemotherapy for hemato-oncological neoplasias and other cancers. Leukemia & Lymphoma 33 65-76.
55. Meirow D 2000 Reproduction post-chemotherapy in young cancer patients. Molecular and Cellular Endocrinology 169 123-131. (doi:10.1016/S0303-7207(00) 00365-8)
56. Meirow D, Nugent D, Epstein M, Livni N & Gosden RG 1998 An in vitro study of the effects of chemotherapy on human primordial follicles. Eur. Soc. Hum Reprod (ESHRE meeting), Goteburg, Sweden.
57. Meirow D, Lewis H, Nugent D & Epstein M 1999 Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Human Reproduction 14 1903-1907. (doi:10.1093/humrep/14.7.1903)
58. Meirow D, Dor J, Kaufman B, Shrim A, Rabinovici J, Schiff E, Raanani H, Levron J & Fridman E 2007 Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy chemotherapy. Potential mechanisms of ovarian injury. Human Reproduction 22 1626-1633. (doi:10.1093/humrep/dem027)
59. Meirow D, Biederman H, Anderson RA & Wallace WH 2010 Toxicity of chemotherapy and radiation on female reproduction. Clinical Obstetrics and Gynecology 53 727-739. (doi:10.1097/GRF.0b013e3181f96b54)
60. Newman H, Finger PT, Chin KJ & Pavlick AC 2011 Systemic bevacizumab (avastin) for exudative retinaldetachment secondary to choroidalmelanoma. European Journal of Ophthalmology 21 796-801. (doi:10.5301/EJO.2011.6477)
61. Nicosia SV, Matus-Ridley M & Meadows AT 1985 Gonadal effects of cancer therapy in girls. Cancer 55 2364-2372. (doi:10.1002/1097-0142 (19850515)55:10〈2364::AID-CNCR2820551011〉3.0.CO;2-E)
62. Nozaki Y, Furubo E, Matsuno T, Fukui R, Kizawa K, Kozaki T & Sanzen T 2009 Collaborative work on evaluation of ovarian toxicity. 6) Two- or four-week repeated-dose studies and fertility study of cisplatin in female rats. Journal of Toxicological Sciences 34 (Suppl 1) SP73-SP81. (doi:10.2131/jts.34.S73)
63. Oktay K, Libertella B & Oktem O 2005 The impact of paclitaxel on menstrual function. Breast Cancer Research and Treatment 94 271s-272s.
64. Oktem O & Oktay K 2007 Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 110 2222-2229. (doi:10.1002/cncr.23071)
65. Oweini H, Otrock ZK, Mahfouz RA & Bazarbachi A 2011 Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Archives of Gynecology and Obstetrics 283 133-134. (doi:10.1007/s00404-010-1501-6)
66. Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V, Levine M, Pritchard KI & National Cancer Institute of Canada Clinical Trials Group 2005 Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study - NCIC CTG MA.5. Journal of Clinical Oncology 23 6002-6008. (doi:10.1200/JCO.2005.07.096)
67. Perez GI, Knudson CM, Leykin L, Korsmeyer SJ & Tilly JL 1997 Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nature Medicine 3 1228-1232. (doi:10.1038/nm1197- 1228)
68. Perez GI, Tao XJ & Tilly JL 1999 Fragmentation and death (a.k.a. apoptosis) of ovulated oocytes. Molecular Human Reproduction 5 414-420. (doi:10.1093/molehr/5.5.414)
69. Perez GI, Maravei DV, Trbovich AM, Cidlowski JA, Tilly JL & Hughes FM Jr 2000 Identification of potassium-dependent and -independent components of the apoptotic machinery in mouse ovarian germ cells and granulosa cells. Biology of Reproduction 63 1358-1369. (doi:10.1095/biolreprod63.5.1358)
70. Pérez-Fidalgo JA, Roselló S, García-Garré E, Jordá E, Martín-Martorell P, Bermejo B, Chirivella I, Guzman C & Lluch A 2010 Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracyclinebased regimens. Breast Cancer Research and Treatment 120 245-251. (doi:10.1007/s10549-009-0426-x)
71. Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE & Sukumvanich P 2006 Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. Journal of Clinical Oncology 24 1045-1051. (doi:10.1200/JCO.2005.03.3969)
72. Plowchalk DR & Mattison DR 1991 Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Toxicology and Applied Pharmacology 107 472-481. (doi:10.1016/0041-008X(91)90310-B)
73. Reh A, Oktem O & Oktay K 2008 Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertility and Sterility 90 1635-1639. (doi:10.1016/j.fertnstert.2007.09.048)
74. Rosendahl M, Andersen CY, Ernst E,Westergaard LG, Rasmussen PE, Loft A & Andersen AN 2008 Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study. Human Reproduction 23 2475-2483. (doi:10.1093/humrep/den248)
75. Schover LR 2008 Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. Journal of Clinical Oncology 26 753-758. (doi:10.1200/JCO.2007.14.1655)
76. Schultheis B, Nijmeijer BA, Yin H, Gosden RG & Melo JV 2012 Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leukemia Research 36 271-274. (doi:10.1016/j.leukres.2011.09.025)
77. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, Mulder J, Green D, Nicholson HS, Yasui Y et al. 2006 Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. Journal of the National Cancer Institute 98 890-896.
78. Stone ER, Slack RS & Novielli A 2000 Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant adriamycin and cytoxan (AC) and adriamycin and cytoxan followed by taxol (ACCT) in early stage breast cancer [abstract]. Breast Cancer Research and Treatment 64 61 (Abstract 224).
79. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z, Elvin JA, Bronson RT, Crum CP & McKeon F 2006 p63 protects the female germ line during meiotic arrest. Nature 444 624-628. (doi:10.1038/nature05337)
80. Takai Y, Matikainen T, Jurisicova A, Kim MR, Trbovich AM, Fujita E, Kim MR, Trbovich AM, Fujita E, Nakagawa T et al. 2007 Caspase-12 compensates for lack of caspase-2 and caspase-3 in female germ cells. Apoptosis 12 791-800. (doi:10.1007/s10495-006-0022-z)
81. Tarumi W, Suzuki N, Takahashi N, Kobayashi Y, Kiguchi K, Sato K & Ishizuka B 2009 Ovarian toxicity of paclitaxel and effect on fertility in the rat. Journal of Obstetrics and Gynaecology Research 3 414-420. (doi:10.1111/j.1447-0756.2009.01023.x)
82. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC & Kramer R 2007 The rates chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. American Journal of Clinical Oncology 30 126-132. (doi:10.1097/01.coc.0000251398.57630.4f)
83. Ting AY & Petroff BK 2010 Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat. Journal of Assisted Reproduction and Genetics 27 591-597. (doi:10.1007/s10815-010-9463-y)
84. Tsai-Turton M, Luong BT, Tan Y & Luderer U 2007 Cyclophosphamide induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicological Sciences 98 216-230. (doi:10.1093/toxsci/ kfm087)
85. Tsujioka S, Ban Y,Wise LD, Tsuchiya T, Sato T, Matsue K, Ikeda T, Sasaki M & Nishikibe M 2009 Collaborative work on evaluation of ovarian toxicity. 3) Effects of 2- or 4- week repeated-dose toxicity and fertility studies with tamoxifen in female rats. Journal of Toxicological Sciences 34 (Suppl 1) SP43-SP51. (doi:10.2131/jts.34.S43)
86. Twelves C, Wong A, Nowacki MP, Abt M, Burris H Jr, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V et al. 2005 Capecitabine as adjuvant treatment for stage III colon cancer. New England Journal of Medicine 352 2696-2704. (doi:10.1056/NEJMoa043116)
87. Witzel ID, Müller V, Harps E, Janicke F & Dewit M 2008 Trastuzumab in pregnancy associated with poor fetal outcome. Annals of Oncology 19 191-192. (doi:10.1093/annonc/mdm542)
88. Yeh J, Kim B, Liang YJ & Peresie J 2006 Müllerian inhibiting substance as a novel biomarker of cisplatin-induced ovarian damage. Biochemical and Biophysical Research Communications 348 337-344. (doi:10.1016/j.bbrc.2006. 06.195)
89. Yeh J, Kim BS, Liang YJ & Peresie J 2008 Baseline and stimulated serum inhibin levels as biomarkers of cisplatin-induced ovarian damage in female rats. American Journal of Obstetrics and Gynecology 198 e1-e6.
90. Yeh J, Kim BS, Peresie J & Page C 2009 Declines in levels of hyperpolarization-activated cation (HCN) channels in the rat ovary after cisplatin exposure. Reproductive Sciences 16 986-994. (doi:10.1177/ 1933719109339217)
91. Yucebilgin MS, Terek MC, Ozsaran A, Akercan F, Zekioglu O, Isik E & Erhan Y 2004 Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. Australian & New Zealand Journal of Obstetrics & Gynaecology 44 6-9. (doi:10.1111/j.1479- 828X.2004.00143.x)
92. Zamah AM, Mauro MJ, Druker BJ, Oktay K, Egorin MJ, Cedars MI & Rosen MP 2011 Will imatinib compromise reproductive capacity? Oncologist 16 1422-1427. (doi:10.1634/theoncologist.2011-0137)
93. Zekri JM, El-Helw LM, Purohit OP, Hatton MQ & Coleman RE 2008 Epirubicin/vinorelbine adjuvant chemotherapy in young women with breast cancer is associated with preservation of menstrual function. Clinical Oncology 20 513-516. (doi:10.1016/j.clon.2008.03.016)
94. Zhou WB, Yin H, Liu XA, Zha XM, Chen L, Dai JC, Tao AD, Chen L, Ma JJ, Ling LJ et al. 2010 Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. BMC Cancer 10 281. (doi:10.1186/1471-2407-10-281)